Jim Cramer’s Game Plan: 15 Stocks in Focus

5. Pfizer Inc. (NYSE:PFE)

Number of Hedge Fund Holders: 80

Cramer expects to hear good news from Pfizer Inc.’s (NYSE:PFE) fourth-quarter and full-year 2024 earnings report.

“We also hear from two huge drug companies, Merck and Pfizer… Pfizer bought Seagen, the old Seattle genetics at the end of 2023. We still haven’t seen the breakout anti-cancer drugs that would justify the deal’s $43 billion price tag. Now maybe we’ll hear something good this quarter. If so, the stock could soar, very little downside at these low levels… Then again, if you want yield in this market, I’d much rather own Merck or Pfizer.”

Pfizer (NYSE:PFE) develops and distributes biopharmaceuticals across various therapeutic areas, including cardiovascular health, infectious diseases, cancer, immunology, and vaccines. The company projects full-year 2025 revenues between $61.0 billion and $64.0 billion, with COVID-19 product revenues expected to remain consistent with 2024, excluding a non-recurring $1.2 billion from Paxlovid in 2024.

Pfizer (NYSE:PFE) expects operational revenue growth for 2025 to range from flat to 5% year-over-year, based on its 2024 baseline guidance. Additionally, the company expects adjusted diluted EPS for 2025 to be between $2.80 and $3.00, reflecting a year-over-year growth of 10% to 18% from the midpoint of its 2024 baseline guidance.